News

PMA Insights: Week 7

17/02/2023
  • CEPs Annual Report indicates reduced time to market access
  • The FDA’s Biosimilar User Fee Amendments III (BsUFA III)
15022023-News-Digest-Wk-7Download

Author:

Amy Rudd, ACIM
About the Author

Article Tags

Biosimilars Funding Gene Therapy & ATMPs HTA PMA Trends Pricing

Share this article

Related articles

Webinar
11.09.2026
Beyond the first JCA: emerging patterns, national ...

The first EU Joint Clinical Assessments (JCAs) are now providing real-world evidence of how the new ...

Read more
Articles
09.09.2026
Choosing payer pricing research? Start with the qu...

Different budget pressures create different payer pricing challenges  Healthcare budget pressur...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch